Divyaswathi Citla Sridhar and Team Report Higher VTE Rates in Obese Users of Certain Estrogen-Progestin Combinations
RPTH Journal shared on LinkedIn:
”Does obesity amplify clot risk with hormonal therapy?
A massive database study from Divyaswathi Citla Sridhar, MD MS and team reports higher VTE rates in obese users of certain estrogen-progestin combinations—but not with progesterone-only therapy.
Curious which regimens carry the greatest risk?
Co-authors: Madhvi Rajpurkar, Lakshmi Srivaths, Bethany Samuelson Bannow, Rachel Rosovsky, and Nancy Sokkary”
Read the full article in RPTH.
Article: Venous thromboembolism in obese hormonal contraceptive users: a large national database study
Authors: Divyaswathi Citla-Sridhar, Madhvi Rajpurkar, Lakshmi Srivaths, Bethany Samuelson Bannow, Rachel P. Rosovsky, Nancy Sokkary
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS